Disperse Orange 25, also known as C.I. Solvent Orange 7, is a synthetic organic dye that is used primarily in dyeing and printing textiles. It is a bright orange color and has good fastness properties. The dye is synthesized by reacting aniline with 4-nitrobenzenesulfonyl chloride. The resulting product is then diazotized and coupled with 2-naphthol. Disperse Orange 25 is considered a potentially harmful substance, and its use in textiles can pose risks to human health and the environment. This is due to its potential for skin sensitization and potential for bioaccumulation. Because of these potential health and environmental concerns, researchers are studying alternative dyes and exploring ways to improve the safety and sustainability of textile dyeing processes.'
disperse orange 25: no further information available 10/95 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 92278 |
| CHEMBL ID | 3561091 |
| SCHEMBL ID | 531129 |
| MeSH ID | M0251714 |
| Synonym |
|---|
| disperse orange 2k |
| c.i. disperse orange 25 |
| serilene orange 2rl |
| transetile orange p-rcl |
| disperse brilliant orange rl |
| latyl orange nst |
| solvent orange 105 |
| dop-2k |
| tersetile orange rcl |
| resiren orange tr |
| foron brilliant orange e-rl |
| einecs 250-654-8 |
| 3-(ethyl(4-((4-nitrophenyl)azo)phenyl)amino)propiononitrile |
| 3-(ethyl(4-((4-nitrophenyl)azo)phenyl)amino)propanenitrile |
| c.i. solvent orange 105 |
| orange 2k nitrodye |
| disperse orange 25 |
| propanenitrile, 3-(ethyl(4-((4-nitrophenyl)azo)phenyl)amino)- |
| 4'-nitrophenylazo-4-(1-cyanoethyl, (n-ethyl)phenylamine) |
| dispersol orange b 2r |
| propionitrile, 3-(n-ethyl-p-((p-nitrophenyl)azo)anilino)- |
| synten orange p-rl |
| artisil brilliant orange rl |
| fantagen orange 2rl |
| disperse orange 25, dye content 95 % |
| AKOS001483272 |
| 3-[n-ethyl-4-[(4-nitrophenyl)diazenyl]anilino]propanenitrile |
| 31482-56-1 |
| propanenitrile, 3-(ethyl(4-(2-(4-nitrophenyl)diazenyl)phenyl)amino)- |
| FT-0625331 |
| propanenitrile, 3-[ethyl[4-[(4-nitrophenyl)azo]phenyl]amino]- |
| AKOS015915549 |
| SCHEMBL531129 |
| dtxsid5051999 , |
| dtxcid2030562 |
| cas-31482-56-1 |
| tox21_303759 |
| NCGC00357057-01 |
| disperseorange25 |
| 3-[ethyl({4-[(1e)-2-(4-nitrophenyl)diazen-1-yl]phenyl})amino]propanenitrile |
| W-110801 |
| 3-[ethyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile |
| ZSPPPAFDNHYXNW-FMQUCBEESA-N |
| propanenitrile, 3-[ethyl[4-[2-(4-nitrophenyl)diazenyl]phenyl]amino]- |
| CHEMBL3561091 |
| 12223-22-2 |
| 12223-19-7 |
| disperse orange 25 |
| c.i.solvent orange 105 |
| FT-0764897 |
| propanenitrile,3-[ethyl[4-[(4-nitrophenyl)azo]phenyl]amino]- |
| STARBLD0009570 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 2.9781 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 16.7095 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 5.9806 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 0.3857 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 1.5916 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 6.1131 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 15.0183 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 13.1130 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 27.3060 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 27.3060 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||